Exploratory Study of Breast Cancer With ABY025

Phase 1

Completed

• Conditions: Breast Cancer

• Registration Number: NCT01216033
• Lead Sponsor: Biomedical Radiation Sciences

Brief Summary

The aim is to study if breast cancer metastases accumulate the newly developed HER2 binding molecule 111-In-ABY025 and if that shows whether the metastases express HER2.

Detailed Description

Not available

Study Timeline

• Study Start: 2010-10
• Study First Submitted: 2010-10-06
• Study First Submitted QC: 2010-10-06
• Study First Posted: 2010-10-07
• Primary Completion: 2011-07
• Study Completion: 2011-07
• Status Verified: 2013-04
• Last Update Submitted: 2013-04-12
• Last Update Posted: 2013-04-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 7

Inclusion Criteria

• female age >20 years
• one or more known metastases localizations

Exclusion Criteria

• other critical disease than breast cancer
• age ≤ 20 years

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Imaging of metastases	One year	Imaging of breast cancer metastases using 111-In-ABY015 for SPECT

Secondary Outcome Measures

Name	Time	Method
Can the new molecule be used for imaging in extended studies	October 2010 - June 2011

Trial Locations

Locations (1)

Akademiska Hospital; 🇸🇪 Uppsala, Uppland, Sweden